DOPAMINE DEFICIENCY IN PARKINSON`S DISEASE AND ITS EFFECT ON MOVEMENT
Keywords:
Parkinson's disease,DOPAL neurotoxicity, alpha-synuclein,dopamineAbstract
Parkinson's disease (PD) is a progressive neurodegenerative disorder that affects motor and cognition functions. The etiology of Parkinson's disease remains largely unknown, but genetic and environmental factors are believed to play a role. The neurotransmitter dopamine is implicated in regulating movement, motivation, memory, and other physiological processes. In individuals with Parkinson's disease, the loss of dopaminergic neurons leads to a reduction in dopamine levels, which causes motor impairment and may also contribute to the cognitive deficits observed in some patients. Important advances in the treatment, etiology, and pathogenesis of Parkinson's disease have been made in the past 50 years. Therefore, this review tries to explain the different possible mechanisms behind the depletion of dopamine in PD patients such as alpha-synuclein abnormalities, mitochondrial dysfunction, and 3,4-dihydroxyphenylacetaldehyde (DOPAL) toxicity, along with the current therapies we have and the ones that are in development.
References
. GBD 2016 Parkinson’s Disease Collaborators (2018) Global, regional, and national burden of Parkinson’s disease, 1990–2016: A systematic analysis for the Global Burden of Disease Study 2016, Lancet Neurol 17, 939–953. [DOI] [PMC free article] [PubMed] [Google Scholar] [2]. Dong-Chen X, Yong C, Yang X, Chen-Yu S, Li-Hua P (2023) Signaling pathways in Parkinson’s disease: Molecular mechanisms and
therapeutic interventions. Signal Transduct Target Ther 8, 73. [DOI] [PMC free article] [PubMed] [Google Scholar]
. Fereshtehnejad S-M, Ghazi L, Shafieesabet M, Shahidi GA, Delbari A, Lökk J (2014) Motor, psychiatric and fatigue features associated with nutritional status and its effects on quality of life in Parkinson’s disease patients, PLoS One 9, e91153. [DOI] [PMC free article] [PubMed] [Google Scholar]
. Palavra NC, Lubomski M, Flood VM, Davis RL, Sue CM (2021) Increased added sugar consumption is common in Parkinson’s disease.
Front Nutr 8, 628845. [DOI] [PMC free article] [PubMed] [Google Scholar]
. Simon N, Gantcheva R, Bruguerolle B, Viallet F (2004) The effects of a normal protein diet on levodopa plasma kinetics in advanced Parkinson’s disease. Parkinsonism Relat Disord 10, 137–142. [DOI] [PubMed] [Google Scholar]
. Rusch C, Flanagan R, Suh H, Subramanian I (2023) To restrict or not to restrict? Practical considerations for optimizing dietary protein interactions on levodopa absorption in Parkinson’s disease. NPJ Parkinsons Dis 9, 98. [DOI] [PMC free article] [PubMed] [Google Scholar]
. Kacprzyk KW, Milewska M, Zarnowska A, Panczyk M, Rokicka G, Szostak-Wegierek D (2022) Prevalence of malnutrition in patients with Parkinson’s disease: A systematic review. Nutrients 14, 5194. [DOI] [PMC free article] [PubMed] [Google Scholar]
. Sheard JM, Ash S, Mellick GD, Silburn PA, Kerr GK (2013) Markers of disease severity are associated with malnutrition in Parkinson’s disease, PLoS One 8, e57986. [DOI] [PMC free article] [PubMed] [Google Scholar]
. Sheard JM, Ash S, Mellick GD, Silburn PA, Kerr GK (2014) Improved nutritional status is related to improved quality of life in Parkinson’s disease. BMC Neurol 14, 212. [DOI] [PMC free article] [PubMed] [Google Scholar]
. Krikorian R, Shidler MD, Summer SS, Sullivan PG, Duker AP, Isaacson RS, Espay AJ (2019) Nutritional ketosis for mild cognitive impairment in Parkinson’s disease: A controlled pilot trial. Clin Park Relat Disord 1, 41–47. [DOI] [PMC free article] [PubMed] [Google Scholar] [11].Damier P, Hirsch EC, Agid Y, Graybiel AM. The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons
in Parkinson's disease. Brain. 1999;122( Pt 8):1437–1448. doi: 10.1093/brain/122.8.1437. [DOI] [PubMed] [Google Scholar]
.Bjorklund A, Dunnett SB. Dopamine neuron systems in the brain: an update. Trends Neurosci. 2007;30:194–202. doi: 10.1016/j.tins.2007.03.006. [DOI] [PubMed] [Google Scholar]
.Chaudhuri KR, Schapira AH. Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment. Lancet Neurol.
;8:464–474. doi: 10.1016/S1474-4422(09)70068-7. [DOI] [PubMed] [Google Scholar]
.Krack P, Hariz MI, Baunez C, Guridi J, Obeso JA. Deep brain stimulation: from neurology to psychiatry? Trends Neurosci. 2010;33:474–
doi: 10.1016/j.tins.2010.07.002. [DOI] [PubMed] [Google Scholar]
.Thobois S, et al. Non-motor dopamine withdrawal syndrome after surgery for Parkinson's disease: predictors and underlying mesolimbic denervation. Brain. 2010;133:1111–1127. doi: 10.1093/brain/awq032. [DOI] [PubMed] [Google Scholar]
